pipeline news from FierceBiotech
NewsBayer strikes deal for Nycomed cancer therapies
A Swiss company's decision to drop its cancer programs will help Bayer beef up its oncology pipeline. Bayer has agreed to buy Nycomed's preclinical cancer therapies in a deal worth up to €52 Read more...
Abbott opens R&D facility, invests $53M
Abbott has opened a new Formulation Development Center at its Illinois headquarters. At the R&D facility, researchers will take candidate molecules and formulate them into tablets and capsules Read more...
Symphogen inks $330M collaboration pact with Genentech
Denmark's Symphogen has inked a $330 million collaboration deal with Genentech to discover new antibodies for three infectious disease Read more...
CytRx inks deal to buy Innovive in $21M acquisition
CytRx has inked a deal to buy Innovive Pharmaceuticals, adding its four experimental oncology therapies to its pipeline. The combined company will own a 49% interest in RXi Pharmaceuticals. The deal Read more...
MedImmune to hire 800 in pipeline push
With plans to double the number of experimental therapies in its pipeline by 2010, MedImmune is laying plans to hire 800 new staffers by the end of this year, according to a report in the Washington Read more...
Exelixis gets $150M credit line
Exelixis has struck a $150 million financing deal with Deerfield Management. At Exelixis discretion, the developer can draw down the money as needed over the next 18 months in $15 million Read more...
Lexicon cuts staff, focuses on R&D
Lexicon is reorganizing and cutting staff as it pursues its aggressive strategy to build its pipeline. The cuts will allow Lexicon to devote its resources to its strategic, business, and clinical Read more...
Merck's osteoporosis drug performs in Phase II
Merck's experimental osteoporosis drug odanacatib turned in positive results in a Phase II trial. The drug reduced measures of bone turnover (breakdown and rebuilding of bone) in women with breast Read more...
Discovery secures $60M financing deal
Struggling Discovery Labs signed a three year, $60 million financing deal with Kingsbridge Capital, a U.K.-based investment group. Kingsbridge will provide the capital through the purchase of newly Read more...
Novartis restructures its development strategy
Novartis CEO Daniel Vasella (photo) tells the Wall Street Journal that he knew Novartis had become too big and too Read more...
| Press ReleasesPRESS RELEASE: GlaxoSmithKline presents innovative neuroscience pipeline GlaxoSmithKline presents innovative neuroscience pipeline Issued on Thursday 13 December 2007 - LSE announcement - GlaxoSmithKline (GSK) plc today presented an overview of its neuroscience portfolio Read more... PRESS RELEASE: Merck Reviews Progress on Strategic Plan at 2007 Annual Business Briefing Merck Reviews Progress on Strategic Plan at 2007 Annual Business Briefing Merck's Pipeline Continues to Progress with Seven Products in Phase III Development Company Expects to File Applications Read more... PRESS RELEASE: Sanofi- aventis: A Promising R&D Portfolio, Well Positioned to Deliver Future Growth Sanofi-aventis: A Promising R&D Portfolio, Well Positioned to Deliver Future Growth PARIS, Sept. 17, 2007--Sanofi-aventis today made announced it plans to have 31 potential submissions by the Read more... |
Get more pipeline coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets